FOR IMMEDIATE RELEASE

Contact: Scott Rosenbush
PL Thomas
Phone: 973-984-0900 x223
Email: scott@plthomas.com

New Study Confirms Safety of
5-LOXIN® AKBA, a natural anti-inflammatory

Morristown, NJ (April 19, 2006) A study published in this month’s issue of Toxicology Mechanisms and Methods demonstrated 5-LOXIN’s broad spectrum of safety. 5-LOXIN is a standardized extract of boswellia serrata, a plant used traditionally in Indian Ayurvedic Medicine to inhibit inflammation.

The gum resin of boswellia serrata contains boswellic acids which are well recognized for safe and effective use in humans. Among the boswellic acids, acetyl-keto-beta boswellic acid (AKBA) has been identified as the most potent inhibitor of mediators of inflammation. 5-LOXIN’s patent-pending manufacturing process provides a standardized 30% AKBA content, the highest available.

In this study, 5-LOXIN was evaluated for acute oral, acute dermal, primary skin and eye irritation, and dose-dependent 90-day sub chronic toxicity. In all cases the results were conclusive, demonstrating a broad spectrum of safety.

According to PLT President Paul Flowerman, “This is an important study affirming 5-LOXIN’s safety in several models, further developing the body of evidence supporting its use.” He continued, “These results are also supported by a recent mutagenicity study, well establishing the safe and effective use of 5-LOXIN.”

In previous published in vitro and in vivo studies, 5-LOXIN significantly inhibited the inflammatory enzyme called 5-lipoxygenase (5-LOX). While not as well recognized as the COX-2 enzyme, it plays a significant role in the expression of inflammation by acting against leukotriene biosynthesis and the expression of the inflammatory mediators I-CAM and V-CAM. 5-LOXIN further has been shown to inhibit MMPs, enzymes that selectively break down connective tissues such as joint cartilage.

Boswellia serrata (frankincense) has been used in traditional Ayurvedic medicine for treatment of inflammation since antiquity, and has been supported clinically. For example, a recent randomized double-blind placebo-controlled study of boswellia in 30 patients for 8 weeks reported significant decrease in knee pain, increased knee flexion, and increased walking distance. The frequency of swelling in the knee joint was significantly decreased.
PL Thomas offers 5-LOXIN internationally in strategic alliance with Laila Nutraceuticals, India.

Laila Nutraceuticals is a leader in process development for standardized herbal extracts and phytochemicals. Laila is a primary manufacturer of these technologies, and supports this work with patents and publications.

PLT has 50 years of experience supplying high quality raw materials from around the world and delivers customized solutions to the Food, Nutraceutical and Cosmeceutical industries.

For more information, please contact Scott Rosenbush at scott@plthomas.com.

# # #